Johnson & Johnson beats sales estimates on pharma strength
Johnson & Johnson on Tuesday beat analysts’ estimates for third-quarter sales, helped by strong demand for its cancer drug Darzalex and Crohn’s disease drug Stelara.
The U.S. health care conglomerate tightened its full-year adjusted profit forecast range.
J&J is the first drugmaker and medical devices firm to report third-quarter earnings and the maintained forecast could be seen as a sign of demand resiliency.
Sales at pharmaceuticals, the company’s largest unit, rose 2.6% to $13.21 billion. That beat estimates of $13.03 billion, according to six analysts polled by Refinitiv.
Read the full story: Johnson & Johnson beats sales estimates on pharma strength
Read More: STOCK MARKET NEWS: Dow climbs over 300 points as markets look to build off solid start to